A phase II combination study of bortezomib with pegylated-liposomal doxorubicin in patients with ovarian cancer failing platinum containing regimens

被引：0
|
作者：
Scambia, G.
Parma, G.
Del Conte, G.
Hess, D.
Gadducci, A.
Katsaros, D.
Sessa, C.
Trudel, G. C.
Coceani, N.
Colombo, N.
机构：
[1] Univ Cattolica Sacro Cuore, Campobasso, Italy
[2] Ist Europeo Oncol, Milan, Italy
[3] Ist Nazl Tumori, I-20133 Milan, Italy
[4] Kantonsspital St Gallen, St Gallen, Switzerland
[5] Univ Pisa, Pisa, Italy
[6] Univ Turin, Turin, Italy
[7] Osped San Giovanni Bellinzona, Bellinzona, Switzerland
[8] Johnson & Johnson, Beerse, Belgium
[9] Sendo, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5581
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5581
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Gemcitabine (G) and liposomal doxorubicin (D) in patients with recurrence of ovarian cancer after chemotherapy containing platinum compounds: a phase II study
    Gambino, Angela
    Tognon, Germana
    Galleri, Guido
    Agoni, Lorenzo
    Pecorelli, Sergio
    ANNALS OF ONCOLOGY, 2004, 15 : 129 - 129
  • [42] Phase lb safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer
    Kim, Kenneth H.
    Jelovac, Danijela
    Armstrong, Deborah K.
    Schwartz, Benjamin
    Weil, Susan C.
    Schweizer, Charles
    Alvarez, Ronald D.
    GYNECOLOGIC ONCOLOGY, 2016, 140 (02) : 210 - 214
  • [43] Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study
    Skarlos, DV
    Kalofonos, HP
    Fountzilas, G
    Dimopoulos, MA
    Pavlidis, N
    Razis, E
    Economopoulos, T
    Pectasides, D
    Gogas, H
    Kosmidis, P
    Bafaloukos, D
    Klouvas, G
    Kyratzis, G
    Aravantinos, G
    ANTICANCER RESEARCH, 2005, 25 (04) : 3103 - 3108
  • [44] Non-pegylated liposomal doxorubicin for patients with recurrent ovarian cancer: A multicentric phase II trial
    Brucker, Janina
    Mayer, Christine
    Gebauer, Gerhard
    Mallmann, Peter
    Belau, Antje Kristina
    Schneeweiss, Andreas
    Sohn, Christof
    Eichbaum, Michael
    ONCOLOGY LETTERS, 2016, 12 (02) : 1211 - 1215
  • [45] Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment
    Vorobiof, DA
    Rapoport, BL
    Mahomed, R
    Karime, M
    MELANOMA RESEARCH, 2003, 13 (02) : 201 - 203
  • [46] A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
    Tadahiro Shoji
    Eriko Takatori
    Hideo Omi
    Masahiro Kagabu
    Tatsuya Honda
    Masayuki Futagami
    Yoshihito Yokoyama
    Michiko Kaiho
    Hideki Tokunaga
    Takeo Otsuki
    Tadao Takano
    Nobuo Yaegashi
    Takanobu Kojimahara
    Tsuyoshi Ohta
    Satoru Nagase
    Shu Soeda
    Takafumi Watanebe
    Hiroshi Nishiyama
    Toru Sugiyama
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 355 - 361
  • [47] A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
    Shoji, Tadahiro
    Takatori, Eriko
    Omi, Hideo
    Kagabu, Masahiro
    Honda, Tatsuya
    Futagami, Masayuki
    Yokoyama, Yoshihito
    Kaiho, Michiko
    Tokunaga, Hideki
    Otsuki, Takeo
    Takano, Tadao
    Yaegashi, Nobuo
    Kojimahara, Takanobu
    Ohta, Tsuyoshi
    Nagase, Satoru
    Soeda, Shu
    Watanebe, Takafumi
    Nishiyama, Hiroshi
    Sugiyama, Toru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (02) : 355 - 361
  • [48] Trabectedin in combination with pegylated liposomal doxorubicin: A retrospective analysis in patients with platinum-sensitive relapsed ovarian cancer.
    Nicoletto, Maria Ornella
    Baldoni, Alessandra
    Casarin, Alessandra
    Nardin, Margherita
    Baretta, Zora
    Randon, Giovanni
    Lardelli, Pilar
    Nieto, Antonio
    Alfaro, Vicente
    Rigamonti, Claudia
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer
    Verschraegen, C. F.
    Czok, S.
    Muller, C. Y.
    Boyd, L.
    Lee, S. J.
    Rutledge, T.
    Blank, S.
    Pothuri, B.
    Eberhardt, S.
    Muggia, F.
    ANNALS OF ONCOLOGY, 2012, 23 (12) : 3104 - 3110
  • [50] Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer Exploratory Analysis of the Phase II PRECEDENT Trial
    Herzog, Thomas J.
    Kutarska, Elzbieta
    Bidzinsk, Mariusz
    Symanowski, Jim
    Binh Nguyen
    Rangwala, Reshma A.
    Naumann, R. Wendel
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (09) : 1580 - 1585
12345